173.08 +0.22 (0.13%)
After hours: 4:26PM EST
|Bid||169.60 x 900|
|Ask||174.74 x 800|
|Day's Range||172.26 - 174.85|
|52 Week Range||146.80 - 179.84|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||53.32|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||2.08 (1.21%)|
|1y Target Est||187.15|
The Zacks Analyst Blog Highlights: Walgreens Boots, Duke Energy, Stryker, Kinder Morgan and PepsiCo
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.
Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.
The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]
U.S. equities have suffered from another bout of harrowing volatility this week as investors scramble to survive this bear market. The Dow Jones Industrial Average is threatening to fall below its multi-month support level to return to lows not seen since the beginning of the year. If those February lows are violated, watch for a possible reversal of much of the 2017 Trump tax cut rally.
Kalamazoo, Michigan, Dec. 04, 2018 -- Kalamazoo, Michigan – December 4, 2018 – Stryker Corporation (NYSE:SYK) announced that its Board of Directors has declared a quarterly.
Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.
Moody's Investors Service ("Moody's") today assigned a Baa1 rating to Stryker Corporation's (Stryker) proposed offering of senior unsecured Euro notes. Stryker's Baa1 ratings reflect its diversified product portfolio across its Orthopedic, MedSurg and Neurotechnology segments. Moody's expects Stryker's leverage will remain low with debt/EBITDA to remain around 2.0-2.25 times.
Kalamazoo, Michigan, Nov. 27, 2018 -- Stryker (NYSE:SYK) announced today that it has priced the following notes: (i) €550 million aggregate principal amount of the Company’s.
Dentsply Sirona’s (XRAY) interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter. The company’s interest income increased from $400,000 in the third quarter of 2017 to $600,000 in the third quarter. Dentsply’s net other expense increased from $900,000 in the third quarter of 2017 to $4.7 million in the third quarter. The company’s provision for income taxes decreased from $7.1 million in the third quarter of 2017 to $4.2 million in the third quarter.
Among the 15 analysts covering Dentsply Sirona (XRAY) in November, five analysts gave a “buy” or a higher recommendation, while ten analysts gave a “hold” recommendation. The mean rating for Dentsply stock is 2.53 with a target price of $46.73, which implies an upside potential of 28% over the closing price of $36.51 on November 23. Peers’ ratings
In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating. The mean rating for Hologic stock is 2.3 with a target price of $45.09, implying an upside potential of 8.5% over Hologic’s closing price of $41.54 on November 21, 2018.
Hologic’s (HOLX) cost of product revenues increased from $881.8 million in fiscal 2017 to $886.6 million in fiscal 2018. Its amortization on intangible assets increased from $297.1 million in fiscal 2017 to $319.4 million in fiscal 2018 due to an increase associated with the Cynosure acquisition partially offset by lower amortization expenses related to the sale of its blood screening business. The company’s gross margin contracted from 64.07% in fiscal 2017 to 62.72% in fiscal 2018.
In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts gave it a “hold” rating. The mean rating for Stryker stock is 1.97 with a target price of $187.32, implying an upside potential of 11.7% over Stryker’s closing price of $167.72 on November 19, 2018.
While the company saw an income tax benefit of $37.0 million in the third quarter of 2017, in the most recent quarter, it incurred an income tax expense of $56.0 million. Stryker’s net income jumped from $434.0 million in the third quarter of 2017 to $590.0 million in the latest quarter, which translated into net earnings per share of $1.55 in the third quarter of 2018. Stryker’s net earnings per share were $1.14 in the third quarter of 2017.
For fiscal 2018 and 2019, Stryker’s gross margin is expected to come in at 66.29% and 66.45%, respectively, as compared with gross margins of 66.31% for fiscal 2017. In comparison, fiscal 2018 gross margins of peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Zimmer Biomet Holdings (ZBH) are expected at 59.29%, 70.43%, and 71.91%, respectively. Stryker incurred selling, general, and administrative expenses of $1.24 billion in the third quarter of 2018 as compared with $1.10 billion in the third quarter of 2017.
Strong operational performance and upward movements in Stryker (SYK) stock have kept investors interested in the stock in 2018. In this series, we’ll explore Stryker’s financials, segment performance, analysts’ views on the stock, and valuation metrics of the company.
Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.
Kalamazoo, Michigan, Nov. 20, 2018 -- Stryker (NYSE:SYK) will participate in the Evercore ISI HealthCONx Conference on Wednesday, November 28, 2018 at the Boston Harbor Hotel.